Pfizer Inc. shares moved higher in the latest session, extending a rebound that has been building steadily since early December as investors reassess the pharmaceutical giant’s earnings stability and income appeal. The stock traded around the mid-$26 level after gaining more than 2% on the day, reflecting renewed interest following a period of prolonged underperformance earlier in the year.

The move higher comes as Pfizer continues to demonstrate earnings resilience despite slower top-line growth expectations. Recent quarterly results showed another earnings beat, with normalized EPS exceeding analyst forecasts, reinforcing the view that cost controls and portfolio optimization are cushioning the impact of post-pandemic normalization in demand. Revenue trends remain mixed, but margins and cash generation have held up better than many peers in the large-cap healthcare space.

From a valuation perspective, Pfizer is increasingly being viewed as a defensive play rather than a growth story. The stock trades at a modest earnings multiple relative to the broader market, while its forward dividend yield north of 6% remains a key draw for income-focused investors. With beta well below market averages, Pfizer is also attracting capital from investors seeking lower volatility exposure amid lingering macro uncertainty.

Looking ahead, analyst estimates point to relatively stable earnings in 2025, with a modest decline expected in revenues before growth resumes in subsequent years. While near-term sales growth remains constrained, management’s focus on pipeline execution, strategic acquisitions, and balance sheet discipline continues to underpin longer-term confidence. As a result, market participants appear more willing to accumulate shares on pullbacks, suggesting that Pfizer may be transitioning from a value trap narrative toward a steadier income and stability profile.